<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Surgical resection of sporadic pancreatic neuroendocrine tumors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Surgical resection of sporadic pancreatic neuroendocrine tumors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Surgical resection of sporadic pancreatic neuroendocrine tumors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Allendorf, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Chabot, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sally E Carty, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stanley W Ashley, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H7791045"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pancreatic neuroendocrine neoplasms (PNENs) are rare, accounting for fewer than 3 percent of all pancreatic tumors [<a href="#rid1">1,2</a>]. PNENs exhibit a wide spectrum of clinical behavior that has made classification and staging difficult. While the majority of PNENs are associated with relatively good survival, there can be significant variability in outcomes based on their biological heterogeneity [<a href="#rid3">3-5</a>]. The classification, epidemiology, clinical presentation, localization, and staging of PNENs is discussed separately. (See  <a class="medical medical_review" href="/d/html/2612.html" rel="external">"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms"</a>.) </p><p>The term "pancreatic neuroendocrine neoplasm" is preferred to encompass a diverse set of tumors arising in the pancreas that share a common progenitor cell [<a href="#rid6">6</a>]. The well-differentiated forms are referred to as pancreatic neuroendocrine tumors (PNETs). In general, poorly differentiated PNENs are high-grade lesions that are referred to as neuroendocrine carcinomas with aggressive biologic behavior, and medical rather than surgical therapy is usually more appropriate. (See  <a class="medical medical_review" href="/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>.) </p><p>This topic will focus predominantly on well-differentiated PNETs. (See <a class="local">'Staging and tumor classification'</a> below.)</p><p>In the past, PNETs were often referred to as pancreatic "islet cell" tumors or pancreatic "carcinoids." With time, the term "carcinoid" has come to mean a very specific group of well-differentiated tumors, predominantly arising in the tubular gastrointestinal tract, which produces only serotonin. However, endocrine tumors of the pancreas can express other hormones or can be biochemically inert. (See  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Classification and terminology'</a>.)</p><p>While most PNETs are sporadic, PNETs can also be associated with genetic syndromes. The surgical management of sporadic PNETs is reviewed here. The management of PNETs associated with genetic syndromes is discussed separately. (See  <a class="medical medical_review" href="/d/html/2026.html" rel="external">"Multiple endocrine neoplasia type 1: Management"</a> and  <a class="medical medical_review" href="/d/html/5193.html" rel="external">"Clinical features, diagnosis, and management of von Hippel-Lindau disease"</a> and  <a class="medical medical_review" href="/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis"</a> and  <a class="medical medical_review" href="/d/html/90123.html" rel="external">"Neurofibromatosis type 1 (NF1): Management and prognosis"</a>.) </p><p class="headingAnchor" id="H352275447"><span class="h1">PREOPERATIVE EVALUATION</span><span class="headingEndMark"> — </span>Surgical planning must take into account the characteristics of the tumor, as well as the patient's overall health and wishes. An accurate history and review of pertinent laboratory and prior imaging studies is essential for planning resection of pancreatic neuroendocrine tumors (PNETs). </p><p class="headingAnchor" id="H13897055"><span class="h2">Genetic background</span><span class="headingEndMark"> — </span>The patient's history and genetic testing help determine whether the tumor is sporadic or associated with a genetic syndrome. This is important because the association of a genetic syndrome, multiple endocrine neoplasia type 1 (MEN1) for instance, affects the number and extent of primary PNETs, which greatly impacts surgical decision making [<a href="#rid7">7,8</a>]. The management of PNETs associated with genetic syndromes is discussed separately. (See  <a class="medical medical_review" href="/d/html/2026.html" rel="external">"Multiple endocrine neoplasia type 1: Management"</a> and  <a class="medical medical_review" href="/d/html/5193.html" rel="external">"Clinical features, diagnosis, and management of von Hippel-Lindau disease"</a> and  <a class="medical medical_review" href="/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis"</a> and  <a class="medical medical_review" href="/d/html/90123.html" rel="external">"Neurofibromatosis type 1 (NF1): Management and prognosis"</a>.) </p><p class="headingAnchor" id="H352275554"><span class="h2">Tumor characteristics</span><span class="headingEndMark"> — </span>Characteristics of a sporadic PNET that are important for determining optimal surgical management include the tumor's functional status, whether the tumor is benign or malignant, and, for malignant tumors, the extent of tumor invasion of contiguous structures and presence or absence of metastatic disease  (<a class="graphic graphic_algorithm graphicRef100577" href="/d/graphic/100577.html" rel="external">algorithm 1</a>). It is extremely difficult to predict the course of disease in the patient with PNET. As an example, a small tumor size does not necessarily mean that it is benign [<a href="#rid9">9</a>]. Similarly, a diagnosis of malignant PNET cannot always be secured or excluded simply based upon histology. The only reliable indicators of a malignant tumor are the presence of invasion, metastases, or tumor recurrence. The natural history of malignant PNETs is also variable, with some large metastatic tumors having a very indolent course and some small, isolated tumors having a very aggressive course. (See  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Morphology and immunohistochemistry'</a>.)</p><p class="headingAnchor" id="H352275740"><span class="h3">Functionality</span><span class="headingEndMark"> — </span>A clinical classification divides sporadic PNETs into functional and nonfunctional tumors. Clinical symptoms and biochemical evidence of hormone excess determine the tumor's functional status (not histologic appearance or the results of immunohistochemical staining). In the preoperative period, once the diagnosis of a functional tumor is made biochemically, the next step is to localize and stage the tumor radiographically. Although functionality may impact prognosis (eg, insulinomas are generally indolent tumors), the biologic behavior of most functional neuroendocrine tumors is defined by the grade and stage of the tumor. (See <a class="local">'Localization and malignant potential'</a> below and <a class="local">'Staging and tumor classification'</a> below and  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Functionality and nomenclature'</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonfunctional</strong> – The majority of PNETs have no defined clinical syndrome and no elevated hormone levels. As such, the presentation of nonfunctional PNETs is often delayed. Patients often present late in their course with symptoms of mass effect or with symptoms related to metastases, including abdominal pain, weight loss, and jaundice [<a href="#rid7">7,10</a>]. As the threshold for abdominal imaging steadily decreases, nonfunctional tumors are frequently identified as incidental findings. (See  <a class="medical medical_review" href="/d/html/2612.html" rel="external">"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms", section on 'Clinical presentation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Functional</strong> – Patients with functional (ie, hormone-secreting) tumors present clinically with syndromes of excess gastrointestinal hormone production (insulin, serotonin, gastrin, VIP [vasoactive intestinal peptide], glucagon, or somatostatin)  (<a class="graphic graphic_table graphicRef111380" href="/d/graphic/111380.html" rel="external">table 1</a>) [<a href="#rid11">11</a>]. In general, the aggressiveness of PNETs (grade based on histologic features) does not correlate with presence or type of hormone production. Once a diagnosis of a functional tumor has been made biochemically, it is generally unnecessary to repeat any studies. (See <a class="local">'Localization and malignant potential'</a> below.)</p><p></p><p class="bulletIndent1">Briefly:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Insulinoma</strong> – Insulinoma is the most common functional neoplasm of the endocrine pancreas. Up to 90 percent of insulinomas are benign, and they can be sporadic or associated with MEN1 syndrome. Most patients present with severe hypoglycemia. (See  <a class="medical medical_review" href="/d/html/2187.html" rel="external">"Insulinoma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastrinoma</strong> – Gastrinomas produce the hormone gastrin. The consequences of hypergastrinemia are gastric acid hypersecretion and its related peptic complications. Patients are classified as having sporadic or familial (ie, associated with MEN1) gastrinoma. This distinction is important as management differs [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2584.html" rel="external">"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>VIPoma</strong> – VIPomas produces the hormone VIP. The consequences of excess VIP secretion include large-volume secretory diarrhea and electrolyte abnormalities. Prior to surgery, all patients with VIPoma require correction of dehydration, hypokalemia, and other metabolic abnormalities. Preoperative <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> administration can reduce the levels of circulating VIP and is the treatment of choice to control large-volume secretory diarrhea and improve electrolyte management [<a href="#rid13">13-15</a>]. (See  <a class="medical medical_review" href="/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucagonoma</strong> – Glucagonomas produce the hormone glucagon. The consequences of excess glucagon secretion are a syndrome that includes a characteristic skin rash (necrolytic migratory erythema,  (<a class="graphic graphic_picture graphicRef73263" href="/d/graphic/73263.html" rel="external">picture 1</a>)), diabetes mellitus, malnutrition, weight loss, thrombophlebitis, glossitis, and anemia. (See  <a class="medical medical_review" href="/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Somatostatinoma</strong> – Somatostatinoma is the least common PNET with a reported incidence of 1 in 40 million people. Excess somatostatin secretion produces a characteristic syndrome that includes steatorrhea, mild diabetes, and cholelithiasis. The diagnosis is typically delayed, and approximately 75 percent have metastasized, often to the liver, at the time of diagnosis. (See  <a class="medical medical_review" href="/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="headingAnchor" id="H352275794"><span class="h3">Localization and malignant potential</span><span class="headingEndMark"> — </span>Preoperative imaging by cross-sectional imaging (computed tomography [CT], magnetic resonance imaging [MRI]), as well as functional somatostatin receptor based diagnostic imaging (Indium-111 pentetreotide SPECT [OctreoScan] or <a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">Gallium Ga-68 DOTATATE</a> or gallium GA-68 DOTATOC PET) with or without endoscopic ultrasound can help localize the tumor and also determine the tumor's benign or malignant nature by determining the degree of local invasion, lymph node involvement, and metastases to the liver or elsewhere. (See  <a class="medical medical_review" href="/d/html/2612.html" rel="external">"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms", section on 'Somatostatin-receptor-based imaging'</a>.)</p><p>For pancreatic tumors, endoscopic ultrasound has a sensitivity ranging from 86 to 93 percent. When combined with spiral CT, the sensitivity approaches 100 percent [<a href="#rid16">16</a>]. Endoscopic fine needle aspiration biopsy of the tumor can confirm the presence of neuroendocrine cells, identify regional lymphadenopathy, and may help determine the proliferative index (eg, Ki67), which in turn can help grade the lesion, which is important for prognostic stratification and treatment. (See <a class="local">'Staging and tumor classification'</a> below.)</p><p class="headingAnchor" id="H13895677"><span class="h3">Staging and tumor classification</span><span class="headingEndMark"> — </span>In 2006 and 2007, the European Neuroendocrine Tumour Society (ENETS) proposed a staging scheme similar to those for most other types of epithelial neoplasms for neuroendocrine tumors (NETs) of the digestive tract, including PNETs; it was accompanied by a histologic grading system that could be applied to all stages of NETs [<a href="#rid17">17,18</a>]. This grading proposal was later endorsed by the joint American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC), although they modified the ENETS tumor, node, metastases (TNM) staging proposal [<a href="#rid19">19</a>]. The newest version of the TNM staging classification (eighth edition, 2017) has a staging system for neuroendocrine tumors of the pancreas  (<a class="graphic graphic_table graphicRef111355" href="/d/graphic/111355.html" rel="external">table 2</a>) that is separate from that used for exocrine pancreatic tumors [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Staging system'</a>.)</p><p>Measures of the proliferative index, like Ki67, are used to assign grades and have also been shown to have prognostic power for PNETs [<a href="#rid20">20-22</a>]. Prior to 2017, there were two categories of tumor classification. Well-differentiated neuroendocrine tumors were separated into low-grade (G1, Ki-67 index &lt;3 percent) and intermediate-grade (G2, Ki-67 index 3 to 20 percent) categories according to proliferative rate. Poorly differentiated tumors were all considered to represent high-grade (G3, Ki-67 index &gt;20 percent) neuroendocrine carcinomas (NECs). However, in recognition of the fact that a subset of high-grade NETs are well to moderately well differentiated, the 2017 World Health Organization (WHO) classification of tumors of endocrine organs modified the grading scheme for pancreatic NETs [<a href="#rid23">23</a>]. Well-differentiated pancreatic NETs are now classified as G1 (PanNET G1), G2 (PanNET G2), or G3 (PanNET G3), and the terminology for high-grade poorly differentiated tumors is PanNEC G3  (<a class="graphic graphic_table graphicRef115945" href="/d/graphic/115945.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on '2010 and 2019 World Health Organization classification'</a>.)</p><p>In general, we prefer the terms "PNET G1," "PNET G2," and "PNET G3" to designate well-differentiated PNETs or varying grades and "PNEC" to designate a high-grade poorly differentiated neuroendocrine neoplasm. The majority of sporadic PNETs are G1 or G2, and they are associated with a relatively prolonged natural history, even when metastatic. PanNEC G3 lesions behave aggressively and are typically treated with systemic chemotherapy, even when apparently localized. (See  <a class="medical medical_review" href="/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>.)</p><p>The natural history and clinical behavior of PNET G3 tumors is in between that of PNET G1/2 tumors and PNEC G3 tumors. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms", section on 'High-grade, well-differentiated tumors (NET G3)'</a>.) </p><p>An important point is that while histologic grade is a useful measure of prognosis, it is not an indicator of whether a PNET is benign or malignant. The only criteria for malignant behavior are the presence of local invasion, metastases, or recurrent disease. </p><p>Earlier classification systems from the WHO had incorporated tumor size (&lt;2 cm, ≥2 cm) into the staging criteria for sporadic PNET. There is evidence that larger tumors are more likely to be intermediate-grade rather than low-grade and that larger tumors are more often malignant and have somewhat poorer outcomes with a higher risk of disease recurrence [<a href="#rid24">24,25</a>]. However, size alone cannot determine malignant potential. Tumors &lt;2 cm can be malignant, and tumors &gt;2 cm can be benign. </p><p class="headingAnchor" id="H18428100"><span class="h2">Medical risk assessment</span><span class="headingEndMark"> — </span>Although sporadic pancreatic neuroendocrine tumors can present at any age, they generally occur in older individuals. The peak incidence is between the fourth and sixth decades, and thus, medical risk assessment should be performed to identify and manage factors that increase the risk of perioperative adverse events. (See  <a class="medical medical_review" href="/d/html/6616.html" rel="external">"Evaluation of cardiac risk prior to noncardiac surgery"</a> and  <a class="medical medical_review" href="/d/html/2793.html" rel="external">"Preoperative evaluation and management of patients with cancer"</a> and  <a class="medical medical_review" href="/d/html/6917.html" rel="external">"Evaluation of perioperative pulmonary risk"</a>.)</p><p class="headingAnchor" id="H18427060"><span class="h1">CANDIDATES FOR RESECTION</span><span class="headingEndMark"> — </span>Surgery is the only known cure for sporadic pancreatic neuroendocrine tumors (PNETs), whether functional or nonfunctional [<a href="#rid26">26-28</a>]. Surgery is indicated in patients with PNETs to alleviate systemic symptoms due to hormone overproduction and compressive symptoms due to local mass effect and to prevent malignant transformation or dissemination [<a href="#rid29">29,30</a>]. </p><p>For some small, PanNEN G1 asymptomatic tumors, active surveillance has emerged as a potentially safe and effective strategy in lieu of surgery. In a meta-analysis of five studies including 327 patients who were observed for asymptomatic small PNETs (although the definition of "small" ranged from 2 cm up to any size diameter), measurable tumor growth was observed in 0 to 51 percent of patients over a median follow-up period of 28 to 45 months [<a href="#rid31">31</a>]. Only 14 percent of patients ultimately required pancreatic resection (most commonly for tumor growth), and there were no disease-related deaths.</p><p>However, there is not complete consensus on which patient population is safe to observe. While the 2016 European Neuroendocrine Tumor Society (ENETS) guidelines and consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) both endorse intensive observation for nonfunctional PNETS &lt;2 cm [<a href="#rid32">32,33</a>], current guidelines from the North American Neuroendocrine Tumor Society (NANETS) recommend observation for PNETS &lt;1 cm but individualized management based on age, comorbidity, growth, grade, extent of needed surgery, and patient preference for tumors between 1 and 2 cm [<a href="#rid34">34</a>]. Thus, until more conclusive data become available, the decision to pursue nonoperative management for small nonfunctional low-grade PNETs should be made individually after weighing risks against benefits. In this context, it is important to remain cognizant of the considerable morbidity and mortality of major pancreatic resections.</p><p>Tumor functionality, grade, and stage are important factors in choosing patients for surgical treatment and determining the operative approach  (<a class="graphic graphic_algorithm graphicRef100577" href="/d/graphic/100577.html" rel="external">algorithm 1</a>). As an example, for patients with a clinical syndrome consistent with insulinoma (most of which are benign), who appear to have an isolated pancreatic lesion, surgical resection is the treatment of choice. Patients with metastatic disease may be considered for debulking surgery if symptoms from excess insulin are refractory to medical treatment. (See <a class="local">'Insulinoma'</a> below.) </p><p>By contrast, the majority of glucagonomas, VIPomas, somatostatinomas, and gastrinomas are malignant. With malignant tumors, the primary consideration in determining surgical treatment is whether or not the patient has distant metastatic disease, whether or not the extrapancreatic disease is potentially resectable, and whether it is high-volume or low-volume. Aggressive resection of PNETs has acceptable morbidity and mortality with studies demonstrating improved survival across all stages of disease, supporting resection for patients with localized, locoregional, and even metastatic disease, as long as the metastatic sites can be completely resected [<a href="#rid7">7,29,30,35-44</a>]. In a review of surgical resection for 125 nonfunctional and functional tumors, the most favorable outcomes were in patients with benign, functional tumors and completely resected, malignant tumors [<a href="#rid29">29</a>]. (See <a class="local">'Tumor characteristics'</a> above.)</p><p>Our approach to patients with sporadic PNET is as follows: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>No metastatic disease</strong> – For patients with well-differentiated PanNEN G1 (&gt;2 cm), G2, or G3 tumors and no evidence of distant metastatic spread of disease, resection with curative intent should be offered to medically fit patients. Regional lymph node involvement does not preclude resection, although it does adversely affect overall survival [<a href="#rid44">44-49</a>]. For patients with locally advanced tumors, vascular resection/reconstruction and extended resections of adjacent organs can be performed with acceptable morbidity and mortality [<a href="#rid45">45,50</a>]. </p><p></p><p class="bulletIndent1">For patients with PanNEC G3 tumors, surgery alone is rarely curative, even for patients with apparently localized disease. Nevertheless, resection may benefit selected patients when used in conjunction with chemotherapy and/or radiation therapy in a multimodality approach. (See  <a class="medical medical_review" href="/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms", section on 'Localized disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potentially resectable metastatic disease</strong> – For patients with potentially resectable metastatic disease (typically isolated hepatic metastases), an aggressive surgical approach that includes resection of metastatic sites can offer the potential for long-term survival [<a href="#rid44">44,45</a>]. (See  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Surgical resection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unresectable metastatic disease</strong> – For patients with unresectable metastatic disease, best medical therapy including long-acting somatostatin analogues is the usual first-line approach. Other therapies, such as ablation, embolization, chemotherapy, and peptide receptor radionuclide therapy (eg, Lutetium-177 dotatate, in patients who progress on long-acting somatostatin analogs), can prolong survival and improve the quality of life. (See  <a class="medical medical_review" href="/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion"</a>.)</p><p></p><p class="bulletIndent1">In some cases, surgery for metastatic disease may be pursued even if complete resection cannot be accomplished. The most common scenario is a patient who has symptoms from hormone secretion that are refractory to medical therapy [<a href="#rid26">26,39,51,52</a>]. Surgical debulking may palliate symptoms and prolong survival in patients with neuroendocrine liver metastases from a functioning tumor [<a href="#rid39">39,40,51,53</a>]. Most authors advocate resection if 90 percent of the known disease can be resected, although there is growing support to resect if as much as 70 percent can be resected.</p><p></p><p class="bulletIndent1">The decision to pursue surgery is a complex one and needs to take into account tumor histology, the volume of metastatic disease, and the growth rate:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with low-volume metastatic, well-differentiated tumors with an indolent growth rate, surgical resection including resection of metastatic sites in conjunction with adjuvant therapies such as ablation, embolization, hormonal therapy, and chemotherapy can prolong and improve the quality of life [<a href="#rid26">26,39,51,52</a>]. Even large tumors can be debulked with the expectation that adjunctive treatment will be used to control unresectable residual disease. (See  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with high-volume metastatic disease with a high growth rate or high-grade histology (ie, PanNEN G3 or PanNEC G3), best medical therapy may include hormone therapy, long-acting somatostatin analogues, or chemotherapy [<a href="#rid53">53-55</a>]. However, even in the presence of metastatic disease, palliative debulking may be indicated for relief of systemic or local symptoms related to hormone production. (See  <a class="medical medical_review" href="/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion"</a> and  <a class="medical medical_review" href="/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms", section on 'Role of surgery'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Whether there is a benefit to resection of a primary, nonfunctional PNET in patients with unresectable metastatic disease is debated. In some (but not all) series, this approach is associated with a modest survival benefit, but it is likely that this is the result of selection bias (ie, patients selected for this approach likely had a significantly lower tumor burden). (See <a class="local">'Nonfunctional'</a> below.) </p><p></p><p class="bulletIndent2">In the absence of symptoms, there is little role for pancreatic resection for treating nonfunctioning tumors in the presence of extensive unresectable extrapancreatic disease. However, there may be a role for resection of the primary tumor in a patient with low-volume extrapancreatic metastatic disease, particularly with a primary involving the pancreatic head. Given the potentially long natural history of PNET, even when metastatic, tumors of the pancreatic head are more likely to result in symptoms (in contrast to those of the distal pancreas) by eroding into the duodenum, resulting in gastrointestinal hemorrhage, or may cause biliary or gastric outlet obstruction. Furthermore, as liver-directed therapies improve for treatment of liver-isolated metastatic disease, resection of the primary in the setting of unresectable liver-"only" disease should be strongly considered. (See <a class="local">'Nonfunctional'</a> below and  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion"</a>.) </p><p></p><p class="headingAnchor" id="H2066835776"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span>The conventional anatomic contraindications for the resection of pancreatic exocrine tumors, such as portal/superior mesenteric vein invasion and nodal or distant metastases, may not apply to patients with advanced PNETs. Perhaps one of the few relative contraindications based on anatomy is wide invasion of the celiac and superior mesenteric arterial axis. At times, surgery of the primary tumor site is beneficial to relieve symptoms. However, as discussed below, for patients with high-grade histology and rapidly progressive metastatic disease, best medical therapy is advised. (See <a class="local">'Candidates for resection'</a> above.)</p><p>Although surgery is the treatment for functional and nonfunctional PNETs, PNET associated with multiple endocrine neoplasia type 1 (MEN1) and Zollinger-Ellison syndrome (ZE syndrome) is typically managed medically, either initially or long-term, due to multifocality and perhaps due to the more indolent nature of these tumors in this setting. Indications for surgery in patients with PNETs associated with MEN1 and other syndromes are discussed separately. (See  <a class="medical medical_review" href="/d/html/2584.html" rel="external">"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)"</a> and  <a class="medical medical_review" href="/d/html/2026.html" rel="external">"Multiple endocrine neoplasia type 1: Management"</a> and  <a class="medical medical_review" href="/d/html/5193.html" rel="external">"Clinical features, diagnosis, and management of von Hippel-Lindau disease"</a> and  <a class="medical medical_review" href="/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis"</a> and  <a class="medical medical_review" href="/d/html/90123.html" rel="external">"Neurofibromatosis type 1 (NF1): Management and prognosis"</a>.)</p><p class="headingAnchor" id="H22377303"><span class="h1">PANCREATIC RESECTION</span><span class="headingEndMark"> — </span>The goal of surgery for sporadic pancreatic neuroendocrine tumors (PNETs) is to resect the tumor for cure or, in appropriate cases, to debulk the tumor  (<a class="graphic graphic_algorithm graphicRef100577" href="/d/graphic/100577.html" rel="external">algorithm 1</a>) [<a href="#rid7">7,56</a>]. Cure is effected by resecting the primary tumor and associated lymph nodes while preserving the maximal amount of pancreatic mass [<a href="#rid7">7,56</a>]. Preoperative selection and extent of surgery are based upon preoperative and/or intraoperative localization of the tumor to reduce the risk of recurrence. The improved sensitivity of <a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">gallium Ga-68 DOTATATE</a> positron emission tomography (PET) scans has decreased the frequency of surgery without localization. (See <a class="local">'Preoperative evaluation'</a> above and <a class="local">'Intraoperative localization'</a> below.)</p><p class="headingAnchor" id="H352277422"><span class="h2">Intraoperative localization</span><span class="headingEndMark"> — </span>If the PNET is not successfully localized preoperatively, complete evaluation of the pancreas and peripancreatic region is necessary intraoperatively. Exploration is aided by visual, manual, and ultrasonographic inspection. Intraoperative ultrasound (IOUS) has become indispensable in localizing occult PNETs and for defining anatomic relationships. For enucleation procedures, intraoperative ultrasound is vital to ensuring a safe resection during enucleation and should be used to ascertain the relative location of the pancreatic duct and how much intervening pancreatic parenchyma lies between the tumor and duct. (See <a class="local">'Enucleation'</a> below.)</p><p>The Kocher maneuver is used to elevate the second portion of the duodenum out of the retroperitoneum  (<a class="graphic graphic_figure graphicRef58768" href="/d/graphic/58768.html" rel="external">figure 1</a>) to allow circumferential exploration of the pancreatic head and uncinate process. The neck, body, and tail of the pancreas can be explored by dividing the gastrocolic ligament to enter the lesser sac. The pancreas is elevated out of the retroperitoneum by dividing the inferior retroperitoneal attachments. </p><p>The ideal intraoperative probe for assessing the pancreas and its ductal system is a 12 MHz hockey stick probe (ie, pancreatic probe). Since the cord on the hockey stick probe comes off at a right angle to the active surface (unlike most probes where the cord comes off in line with the active surface), this configuration allows for a more ergonomic interrogation of the pancreas. For laparoscopic operations, a low-profile linear laparoscopic probe may be used. <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">Saline</a> may be instilled in the area to create a standoff (ie, increasing the distance between the probe and the pancreas to enhance the near field). Extrapancreatic sites including the duodenum, splenic hilum, small bowel, mesentery, and peripancreatic lymph nodes also must be explored. Through the meticulous combination of visual inspection, manual palpation, and IOUS, PNETs can be localized and defined, and the appropriate operation can be executed.</p><p class="headingAnchor" id="H18429702"><span class="h2">Extent of resection</span><span class="headingEndMark"> — </span>A complete surgical resection involves removing the primary tumor as well as any lymph node metastases that may be present while preserving the maximal amount of pancreatic mass [<a href="#rid7">7,56</a>]. A variety of pancreatic resections, including traditional resections and pancreas-sparing resections, are used to treat PNETs. These are described below, and technical aspects of these procedures are discussed in more detail in the provided links. (See <a class="local">'Traditional resections'</a> below and <a class="local">'Pancreas-sparing resections'</a> below.)</p><p>PNETs that require traditional resection are usually larger, locally advanced, involve the common bile or pancreatic duct, and/or have evidence of lymph node or liver metastases. Nonfunctioning tumors typically present later in the disease course and are typically larger than functional tumors at the time of discovery and thus are not as often amenable to parenchyma-sparing operations. Traditional resection with appropriate lymphadenectomy is recommended for most patients with a nonfunctional PNET who have no evidence of metastatic disease [<a href="#rid26">26,52</a>].</p><p>Preoperative or intraoperative localization of the tumor determines the type of resection needed. (See <a class="local">'Localization and malignant potential'</a> above and <a class="local">'Intraoperative localization'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>For lesions located in the head, uncinate, or neck of the pancreas, pancreaticoduodenectomy is preferred for most lesions. Some lesions may be amenable to enucleation. (See <a class="local">'Pancreaticoduodenectomy'</a> below and <a class="local">'Enucleation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For lesions located in the body or tail of the pancreas, distal pancreatectomy can be performed. If the lesion is thought to be benign, splenic preservation may be attempted. When malignancy is suspected, distal pancreatectomy with splenectomy and peripancreatic lymphadenectomy should be performed. Some small lesions may be amenable to central pancreatectomy or enucleation. (See <a class="local">'Central pancreatectomy'</a> below and <a class="local">'Distal pancreatectomy'</a> below and <a class="local">'Enucleation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For multifocal disease, which is rare, total pancreatectomy is required because disease is present throughout the entire pancreas. (See <a class="local">'Total pancreatectomy'</a> below.)</p><p></p><p class="headingAnchor" id="H18429708"><span class="h3">Traditional resections</span><span class="headingEndMark"> — </span>Traditional resections include pancreaticoduodenectomy, distal pancreatectomy, and total pancreatectomy. </p><p class="headingAnchor" id="H18431351"><span class="h4">Pancreaticoduodenectomy</span><span class="headingEndMark"> — </span>For PNETs in the head of the pancreas that are not amenable to enucleation, pancreaticoduodenectomy is the operation of choice. Conventional pancreaticoduodenectomy involves removal of the pancreatic head, duodenum, first 5 to 10 cm of the jejunum, common bile duct, gallbladder  (<a class="graphic graphic_figure graphicRef82519" href="/d/graphic/82519.html" rel="external">figure 2</a>), and a portion of the stomach. When oncologically appropriate, a pylorus-preserving pancreaticoduodenectomy can be performed. (See  <a class="medical medical_review" href="/d/html/91408.html" rel="external">"Surgical resection of lesions of the head of the pancreas", section on 'Pancreaticoduodenectomy'</a>.)</p><p class="headingAnchor" id="H18431402"><span class="h4">Distal pancreatectomy</span><span class="headingEndMark"> — </span>Distal pancreatectomy involves removal of the body and tail of the pancreas (to the left of the superior mesenteric artery and vein). The traditional procedure includes splenectomy; however, a spleen-preserving technique reduces the risk of postsplenectomy sepsis and related infections [<a href="#rid57">57,58</a>]. For PNETs with a low risk of malignancy, a spleen-preserving technique is preferred. The spleen typically is preserved on a splenic vein and artery pedicle, but some authors advocate using a short gastric pedicle [<a href="#rid59">59,60</a>]. (See  <a class="medical medical_review" href="/d/html/5660.html" rel="external">"Surgical resection of lesions of the body and tail of the pancreas", section on 'Distal pancreatectomy'</a>.)</p><p class="headingAnchor" id="H18431410"><span class="h4">Total pancreatectomy</span><span class="headingEndMark"> — </span>Total pancreatectomy removes nearly all or the entire pancreas. (See  <a class="medical medical_review" href="/d/html/101385.html" rel="external">"Total pancreatectomy"</a>.) </p><p class="headingAnchor" id="H18430484"><span class="h3">Pancreas-sparing resections</span><span class="headingEndMark"> — </span>With advances in surgical technique and the advent of laparoscopy, parenchyma-sparing operations, which include enucleation and central pancreatectomy, are gaining wider acceptance in the management of sporadic PNETs. Parenchyma-sparing operations have the benefit of tumor removal with minimal loss of pancreatic parenchyma [<a href="#rid16">16</a>]. Pancreas preservation may help to avoid pancreatic endocrine and exocrine insufficiency and, for tumors of the body/tail of the pancreas, spare the spleen. Parenchyma-sparing operations decrease postoperative insulin requirements when compared with more traditional resections [<a href="#rid57">57,58</a>]. Parenchyma-sparing operations are generally safe and effective for the management of small (&lt;3 cm), nonfunctional PNETs without overt malignant features; however, even small PNETs may have lymph node disease, so when suspected, a traditional resection (pancreatic head resection, pancreatic tail resection) is indicated [<a href="#rid61">61</a>]. </p><p class="headingAnchor" id="H18431315"><span class="h4">Central pancreatectomy</span><span class="headingEndMark"> — </span>Central pancreatectomy  (<a class="graphic graphic_figure graphicRef90082" href="/d/graphic/90082.html" rel="external">figure 3</a>) is a parenchyma-sparing technique that removes the neck and proximal body of the pancreas while preserving the head and tail of the pancreas. Central pancreatectomy offers better preservation of pancreatic function with acceptable morbidity and mortality [<a href="#rid60">60,62-67</a>]. Central pancreatectomy can be used for selected patients with small, benign, or low-grade PNETs of the neck or proximal body of the pancreas that cannot be enucleated [<a href="#rid60">60,62-69</a>]. (See  <a class="medical medical_review" href="/d/html/5660.html" rel="external">"Surgical resection of lesions of the body and tail of the pancreas", section on 'Central pancreatectomy'</a>.) </p><p>Although central pancreatectomy has been performed laparoscopically, most series describe an open approach. Central pancreatectomy is technically challenging, and some studies report longer operative times and higher surgical morbidity [<a href="#rid70">70-73</a>]. Higher morbidity is attributed to the need to transect the pancreas in two locations, which, in the setting of benign or low-grade disease, is most often through pancreas with a soft texture and associated with higher rates of postoperative pancreatic fistula. </p><p>A single-institution study reviewed 73 central pancreatectomies and performed a matched-pair analysis to distal pancreatectomy [<a href="#rid58">58</a>]. The overall incidence of complications was 41 percent, with pancreatic fistula occurring in 21 percent. There were no deaths. These findings are consistent with those of other large series. There were no differences in fistula, morbidity, and mortality rates between central pancreatectomy and distal pancreatectomy groups. Patients undergoing central pancreatectomy had a lower incidence of new-onset or worsened diabetes than those undergoing distal pancreatectomy. Significantly fewer patients require insulin after central pancreatectomy, offering properly selected patients a better chance for a long-term, insulin-free lifestyle. </p><p class="headingAnchor" id="H18431209"><span class="h4">Enucleation</span><span class="headingEndMark"> — </span>Enucleation allows for maximal preservation of pancreatic tissue while avoiding the complications associated with pancreatic and bowel anastomoses, division of the pancreatic duct, and postgastrectomy complications. (See  <a class="medical medical_review" href="/d/html/91408.html" rel="external">"Surgical resection of lesions of the head of the pancreas", section on 'Enucleation procedures'</a> and  <a class="medical medical_review" href="/d/html/5660.html" rel="external">"Surgical resection of lesions of the body and tail of the pancreas", section on 'Enucleation procedures'</a>.)</p><p>Enucleation is safe and is not detrimental to long-term survival for appropriately selected patients (eg, small, functional PNET in the pancreatic head, or possibly small, nonfunctional PanNEN G1 tumor if active surveillance is considered inappropriate). (See <a class="local">'Staging and tumor classification'</a> above.)</p><p>Enucleation may be attempted for insulinoma and gastrinoma &lt;2 cm that are not abutting the pancreatic duct, as these are likely to be benign [<a href="#rid26">26-28,74</a>]. Enucleation is not appropriate for duodenal wall gastrinoma and is contraindicated for other types of functional tumors (often malignant), and for large tumors (ie, &gt;3 cm; judgment call for tumors ≥2 to 3 cm), in the presence of nodal or metastatic disease or when lesions are in close proximity to the common bile or pancreatic duct. However, for some patients who do not wish to have a traditional resection, or patients with significant comorbidities who may not withstand traditional resection, enucleation may also be appropriate. </p><p>Enucleation has a lower mortality rate but similar morbidity compared with traditional resections. In particular, the rate of pancreatic fistula was roughly equivalent, but the severity was of lower grade using the International Study Group on Pancreatic Fistulas (ISGPF) criteria after enucleation [<a href="#rid30">30</a>]. Prior to enucleation, some advocate preoperative placement of pancreatic duct stents to more easily identify a major ductal disruption if it happens. Due to the relatively high leak rate of this operation, a drain is often placed in the area of resection. </p><p>A multicenter review compared outcomes of enucleation procedures (n = 36) with traditional resection (n = 86) in patients with small (≤3 cm) pancreatic, ampullary, and duodenal neuroendocrine tumors without evidence of metastatic disease [<a href="#rid30">30</a>]. Enucleation procedures included surgical pancreatic enucleation, transduodenal ampullary excision, and duodenal wall excision. Traditional resections included central pancreatectomy, distal pancreatectomy, pancreaticoduodenectomy, and total pancreatectomy. Tumors that were enucleated were more likely to be functional tumors located in the head of the pancreas and less likely to result in splenectomy. The estimated overall morbidity and five-year survival were similar between the enucleation and resection groups. Although the rate of pancreatic fistula was significantly higher in the enucleation group, the fistulas tended to be less severe after enucleation than after resection. For patients with pancreatic head tumors, enucleation was associated with decreased blood loss, operative time, and length of hospital stay compared with pancreaticoduodenectomy.</p><p>Enucleation is more controversial for <strong>nonfunctional</strong> PNETs smaller than 2 to 3 cm. Although traditional resection is preferred over enucleation for nonfunctional PNETs smaller than 2 to 3 cm in size, enucleation is an option for a PanNEN G1 tumor. In one large multi-institutional review comparing enucleation with traditional resection, patients had a similar five-year survival, and although patients undergoing enucleation had a significantly increased rate of pancreatic fistula, the severity of pancreatic fistula had tended toward a lower severity [<a href="#rid30">30</a>]. For this reason, the authors concluded that enucleation and traditional resection had equivalent outcomes for the management of small, nonfunctional PNETs. By contrast, another study found that even PNETs smaller than 3 cm carried a risk of lymph node metastases [<a href="#rid9">9</a>]. In a single-institution review of 318 patients with sporadic, nonfunctional PNETs, lymph node metastases were present in 14 percent of tumors &lt;1 cm, 9 percent of tumors between 1 and 1.9 cm, and 37 percent of tumors between 2 and 2.9 cm. The presence of positive lymph nodes was a predictor of poorer survival on multivariate analysis.</p><p class="headingAnchor" id="H185174391"><span class="h2">Minimally invasive resection</span><span class="headingEndMark"> — </span>With advances in surgical technique and the advent of laparoscopy, minimally invasive operations are gaining wider acceptance in the management of PNETs. There are descriptions and small series of minimally invasive approaches to most of the types of traditional pancreatic resections. These include laparoscopic and robotic techniques for everything from enucleation to pancreaticoduodenectomy. The location of the port sites or incision is based upon the location of the tumor. (See  <a class="medical medical_review" href="/d/html/15103.html" rel="external">"Abdominal access techniques used in laparoscopic surgery"</a>.)</p><p>The most commonly performed minimally invasive pancreatic operations are laparoscopic enucleations and laparoscopic distal pancreatectomy. Laparoscopic distal pancreatectomy with spleen preservation is an option for benign, small PNETs located in the body or tail of the pancreas. Laparoscopic distal pancreatectomy can be performed with or without preservation of the spleen. Although central pancreatectomy has been performed laparoscopically, most reports describe an open approach. (See <a class="local">'Enucleation'</a> above and <a class="local">'Central pancreatectomy'</a> above and <a class="local">'Distal pancreatectomy'</a> above.)</p><p>The benefits of laparoscopic resection for PNETs include reduced postoperative pain, reduced hospital stay, faster recovery, and better cosmesis [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/d/html/5660.html" rel="external">"Surgical resection of lesions of the body and tail of the pancreas", section on 'Open surgical versus minimally invasive distal pancreatectomy'</a>.)</p><p>A review of 130 resections for PNETs noted that minimally invasive and parenchyma-sparing operations for these tumors were safe, feasible, and associated with shorter hospital stays [<a href="#rid76">76</a>]. A single-institution review evaluated 49 consecutive patients who underwent laparoscopic pancreatic surgery for PNETs, including 33 functional tumors and 16 nonfunctional tumors [<a href="#rid16">16</a>]. Laparoscopic resections included 22 enucleations, 15 spleen-preserving distal pancreatectomies, and 8 distal pancreatectomies with splenectomy. The estimated blood loss and operating times were lower in the laparoscopic enucleation group compared with the other laparoscopic groups, though overall complications, including pancreatic fistula, were higher in the laparoscopic enucleation group. The severity of fistula also was higher in the laparoscopic enucleation group. Overall morbidity was higher in the splenic preservation laparoscopic distal pancreatectomy group compared with laparoscopic distal pancreatectomy with splenectomy. There were no differences in length of hospital stay between all the laparoscopic approaches. </p><p>Robotic surgery has also been used in the treatment of PNETs. In a propensity score matched retrospective study of 120 patients with small (&lt;2 cm) PNETs, robotic enucleation was associated with less blood loss (33 versus 80 mL), a shorter duration of surgery (117 versus 150 minutes), and a shorter length of hospital stay (12 versus 13.5 days) compared with open surgery [<a href="#rid77">77</a>]. The two groups had similar complication rates, including those of postoperative pancreatic fistula. The three-dimensional view and ability to articulate instruments using the robotic platform have extended the benefits of minimally invasive pancreatic surgery to a larger population of patients.</p><p class="headingAnchor" id="H352276056"><span class="h1">TECHNIQUES FOR SPECIFIC PNETS</span></p><p class="headingAnchor" id="H14460032"><span class="h2">Nonfunctional</span><span class="headingEndMark"> — </span>For most patients with nonfunctional pancreatic neuroendocrine tumors (PNETs) who have no evidence of metastatic disease, traditional resection with appropriate lymphadenectomy is recommended [<a href="#rid26">26,52</a>]. (See <a class="local">'Pancreatic resection'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Parenchyma-sparing operations (eg, enucleation, central pancreatectomy) are generally safe and effective for the management of small (2 to 3 cm), nonfunctional PNETs without overt malignant features; however, even small PNETs may have lymph node disease [<a href="#rid9">9,30,61</a>]. In a single-institution review of 318 patients with nonfunctional tumors, lymph node metastases were present in 14 percent of tumors &lt;1 cm, 9 percent of tumors between 1 and 1.9 cm, and 37 percent of tumors between 2 and 2.9 cm [<a href="#rid9">9</a>]. The presence of positive lymph nodes was a predictor of poorer survival on multivariate analysis. As a result, traditional resection remains preferred rather than enucleation for nonfunctional PNETs smaller than 2 to 3 cm in size. Nevertheless, enucleation can be an appropriate choice in certain clinical circumstances, such as in those with a small PanNEN G1 tumor. In one multi-institutional review comparing enucleation versus traditional resection, patients had a similar five-year survival [<a href="#rid30">30</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Large (&gt;3 cm), nonfunctional tumors with malignant features with indications for surgery require traditional oncological resection to achieve negative margins. Large tumors are debulked with intent to cure with the expectation that adjunctive treatment will be used for metastatic disease. In the appropriate clinical situation, a parenchyma-sparing resection may be appropriate for patients with larger nonfunctional tumors and significant comorbidities and/or who do not wish to have a traditional resection. </p><p></p><p>Surgical resection may also be pursued in patients with metastatic disease. As noted above, the main considerations in determining whether a patient with a nonfunctional PNET is a candidate for surgery is whether the extrapancreatic disease is potentially resectable, whether it is high volume or low volume, the histology, and the growth rate. (See <a class="local">'Tumor characteristics'</a> above and <a class="local">'Candidates for resection'</a> above.)</p><p>There are advocates of resecting the primary in the setting of metastatic disease [<a href="#rid26">26,28,52,74</a>] and those who disagree [<a href="#rid78">78</a>]. In our view, these situations must be individualized and considered in the context of a long-term strategy for disease control. Bulky disease in the pancreatic head will likely produce significant symptoms. In general, if the tumor is relatively low-grade and the metastatic tumor burden is not large, quality of life will be improved by resection of the primary. In addition, if the metastatic disease is isolated to the liver, resection of the primary combined with local liver-directed therapy may allow the patient to avoid long-term systemic therapy and its side effects. </p><p>In most (but not all [<a href="#rid78">78</a>]) series, removal of the primary tumor has been associated with longer survival, even in cases of unresectable metastatic disease [<a href="#rid35">35,37,38,79</a>]. As an example, in an analysis of 2158 patients with metastatic nonfunctioning PNETs, removal of the primary tumor was associated with a median survival of 4.8 years compared with one year in patients whose primary tumor was not resected [<a href="#rid42">42</a>]. In another review of 163 patients with malignant nonfunctional PNETs, patients able to undergo complete resection of localized disease had prolonged median survival (7.1 versus 5.2 years) [<a href="#rid80">80</a>]. However, it remains possible that this apparent survival benefit is the result of selection bias (ie, patients selected for this approach likely had a significantly lower tumor burden) [<a href="#rid29">29,35,38,43,80</a>]. For this reason, resection of the primary tumor in patients with unresectable metastatic disease remains controversial.</p><p>An important point is that these patients are at high risk for recurrence and require postoperative surveillance for the detection of disease progression. (See <a class="local">'Posttreatment surveillance and re-resection'</a> below.) </p><p class="headingAnchor" id="H14460145"><span class="h2">Functional</span><span class="headingEndMark"> — </span>There is general consensus that sporadic, functional PNETs should be resected to relieve symptoms whenever possible and clinically appropriate [<a href="#rid26">26-28,74</a>]. The main consideration in determining the best treatment for functional PNETs is whether the patient has potentially resectable metastatic disease, the histology, growth rate, and whether symptoms from hormone secretion are refractory to medical therapy [<a href="#rid26">26</a>]. (See <a class="local">'Candidates for resection'</a> above.)</p><p>Traditional resection with appropriate lymphadenectomy, rather than a more limited resection or enucleation, is recommended for patients with functional PNETs &gt;2 cm, which have a higher risk of malignancy and potential for nodal disease, and/or those that are abutting the pancreatic duct and have no evidence of metastatic disease [<a href="#rid26">26-28,52,74</a>]. </p><p class="headingAnchor" id="H7792276"><span class="h3">Insulinoma</span><span class="headingEndMark"> — </span>Insulinoma, which is the most common functioning neoplasm of the endocrine pancreas, is typically benign. Insulinoma can be sporadic or associated with multiple endocrine neoplasia type 1 (MEN1) syndrome, which requires a different surgical approach. Sporadic insulinomas tend to be solitary lesions that respond well to limited resection, whereas MEN1-associated tumors are often multifocal and may require more extensive resections. (See  <a class="medical medical_review" href="/d/html/2187.html" rel="external">"Insulinoma", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/2026.html" rel="external">"Multiple endocrine neoplasia type 1: Management"</a>.) </p><p>Sporadic insulinomas are found with equal frequency in each of the sections of the pancreas [<a href="#rid81">81</a>]. Although<strong> </strong>sporadic insulinomas are most often solitary, they can be multiple in 10 percent of patients [<a href="#rid2">2</a>], and thus, it is necessary to confirm the lesion's location and rule out the presence of other tumors preoperatively or intraoperatively with palpation and intraoperative ultrasound. It is often necessary to perform an extended Kocher maneuver  (<a class="graphic graphic_figure graphicRef58768" href="/d/graphic/58768.html" rel="external">figure 1</a>) of the duodenum to the level of the superior mesenteric vein to allow bimanual palpation or intraoperative ultrasound of the entire head and uncinate process to plan either an anterior or posterior approach to the lesion. The size of the tumor and its location in relation to the common bile and/or pancreatic duct determines whether the tumor can be enucleated or should be removed using a more traditional resection. Most insulinomas are located along the edges of the body or tail. (See <a class="local">'Intraoperative localization'</a> above.)</p><p>If the tumor cannot be localized, blind distal pancreatectomy is no longer advocated. In the case of a nonlocalized tumor, postoperative selective arterial calcium stimulation with hepatic venous sampling should be performed [<a href="#rid82">82</a>]. This test involves drawing hepatic venous samples after selective calcium infusion into the splenic, gastroduodenal, and superior mesenteric arteries [<a href="#rid83">83</a>].</p><p>Enucleation can be attempted for small insulinomas (&lt;2 cm) that are not abutting the pancreatic duct [<a href="#rid16">16,26-28,30,74</a>]. Insulinomas located on the anterior or posterior surfaces of the neck, body, or tail with a tissue plane between the tumor and the pancreatic duct can usually be enucleated. However, insulinoma &gt;2 cm and/or abutting the pancreatic duct, and those without a clear plane between the tumor capsule and pancreatic parenchyma, should be removed via a traditional resection. When the lesion is larger (&gt;2 cm) and/or involves the common bile or pancreatic duct or does not have a clear plane between the tumor capsule and pancreatic duct, a more traditional resection should be performed. Ten percent of insulinomas are malignant and demonstrate local infiltration of lymph nodes or liver metastases. Peripancreatic lymph node dissection should be performed in the rare patient with malignant insulinoma. In the presence of liver metastases, resection of the primary tumor and accessible metastases is advocated if it can be done safely. Tumor debulking helps reduce hypoglycemic symptoms and improves long-term survival. If a tumor is deemed unresectable, medications can be employed to minimize hypoglycemia and the progression of disease [<a href="#rid84">84-86</a>]. Following these guidelines, the cure rate for insulinoma is close to 100 percent [<a href="#rid74">74,87,88</a>]. </p><p class="headingAnchor" id="H7791138"><span class="h3">Gastrinoma</span><span class="headingEndMark"> — </span>Gastrinomas produce the hormone gastrin. The consequences of hypergastrinemia are gastric acid hypersecretion and its related complications. Patients with gastrinoma are classified as having either sporadic or familial gastrinoma. This distinction is important because the pathophysiology, natural history, and medical management differs [<a href="#rid12">12</a>]. The management of gastrinoma associated with MEN1 is reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/2584.html" rel="external">"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)"</a> and  <a class="medical medical_review" href="/d/html/2026.html" rel="external">"Multiple endocrine neoplasia type 1: Management"</a>.) </p><p>Laparotomy is recommended for most patients with a sporadic gastrinoma to define the extent of disease and to achieve curative resection when possible. Although gastrinomas can have histologic features that appear benign and tend to be indolent in nature, most have malignant potential and can grow and metastasize. Early laparotomy and resection, even with incomplete resection of gastrinoma tissue, appears to favorably affect the natural history. In general, the cure rate for sporadic, nonmetastatic gastrinoma is 60 percent and 30 to 40 percent, respectively, at one and five years [<a href="#rid12">12,74,89,90</a>]. </p><p>Gastrinomas may be single or multiple and are often duodenal (approximately two-thirds arise in the duodenal wall) or extrapancreatic in location. These tumors are typically found in the so-called "gastrinoma triangle," which is delineated by the junction of the cystic and common bile duct, the junction of the second and third portion of duodenum, and the junction of the body and neck of the pancreas [<a href="#rid81">81</a>]. At surgery, a thorough exploration of the abdomen, including the liver, is required. The lesser sac should be opened, and bimanual palpation of the body and tail of the pancreas should be performed. A Kocher maneuver with inspection and palpation of the head of the pancreas and lymph nodes behind the uncinate process should also be performed. The surgeon should look and feel for small duodenal wall and submucosal tumors by performing a duodenotomy if necessary. The routine use of duodenotomy and intraoperative ultrasound has resulted in detection of gastrinoma in the majority of patients who are explored [<a href="#rid91">91</a>]. Multiple lymph node biopsies should be taken to obtain a tissue diagnosis.</p><p>The type and extent of resection depends on the location of the gastrinoma. Ideally, all gastrinoma tissue is resected. Regional lymphadenectomy should also be performed as required. Small gastrinomas (&lt;2 cm) in the head of the pancreas can be enucleated as these are likely to be benign, though larger tumors may require pancreaticoduodenectomy [<a href="#rid8">8,92</a>]. Enucleation may be attempted for small pancreatic gastrinomas that are not abutting the pancreatic duct [<a href="#rid26">26-28,74</a>]. Small tumors in the duodenal wall may be amenable to full-thickness excision and primary closure. With gastrinoma &gt;2 cm, there is a higher risk of malignancy and potential for nodal disease, and these should be removed via a traditional resection. Gastrinomas in the body or tail of the pancreas are best managed with a distal pancreatectomy. Although enucleation has been described for pancreatic tail lesions, traditional resection is preferred because of the more aggressive nature of gastrinoma to the left of the superior mesenteric vein [<a href="#rid93">93</a>]. </p><p>The role of laparoscopy in the surgical management of gastrinomas is controversial. Open operations are still more commonly performed for gastrinoma because they commonly are not localized preoperatively, are often located in the duodenum, and are commonly associated with lymph node metastases. Indeed, accessing the "gastrinoma triangle" where most gastrinomas are located can be difficult laparoscopically [<a href="#rid16">16</a>]. In the past, if the tumor was not able to be localized, a parietal cell vagotomy or total gastrectomy was performed. With the advent of proton pump inhibitors, these procedures are no longer advocated. </p><p class="headingAnchor" id="H185180803"><span class="h3">Others</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VIPoma</strong> – Before resection, all patients with VIPoma require correction of dehydration, hypokalemia, and other metabolic abnormalities. Preoperative <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> administration can reduce the levels of circulating VIP. (See  <a class="medical medical_review" href="/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1">Preoperative localization of the VIPoma is essential because 10 percent of patients have extrapancreatic tumors in the retroperitoneum or chest. All patients with localized tumors on preoperative imaging should undergo surgical exploration. </p><p></p><p class="bulletIndent1">Most VIPomas are located in the body or tail of the pancreas and can be managed with a distal pancreatectomy [<a href="#rid94">94</a>]. More than 60 percent of VIPomas are malignant, with up to 60 percent having metastasized to lymph nodes, liver, kidneys, or bone [<a href="#rid16">16</a>]. In one study, only 44 percent of VIPomas were resectable, and of those, only 28 percent were resectable for cure [<a href="#rid95">95</a>]. Thus, careful evaluation of the lymph nodes and liver must be performed preoperatively and intraoperatively. In the case of liver metastases, debulking surgery may be indicated for symptomatic management of diarrhea. (See  <a class="medical medical_review" href="/d/html/15094.html" rel="external">"Overview of hepatic resection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucagonoma</strong> – (See  <a class="medical medical_review" href="/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1">Glucagonomas are usually located in the body or tail of the pancreas and can be managed with a distal pancreatectomy [<a href="#rid94">94</a>]. These tumors are typically large and most often metastatic. Careful evaluation of the liver is necessary. Surgical resection should aim to remove all tumors for potential cure or debulk as much tumor mass as possible for symptomatic relief [<a href="#rid96">96</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Somatostatinoma</strong> – (See  <a class="medical medical_review" href="/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1">Most somatostatinomas are solitary and located in the head of the pancreas or duodenum and can be managed with pancreaticoduodenectomy. Resection of the primary tumor with debulking of metastatic disease has been recommended [<a href="#rid97">97</a>]. (See <a class="local">'Pancreaticoduodenectomy'</a> above and  <a class="medical medical_review" href="/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management", section on 'Pancreatic resection'</a> and  <a class="medical medical_review" href="/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management", section on 'Liver-directed therapy for metastatic disease'</a>.)</p><p></p><p class="headingAnchor" id="H18426593"><span class="h1">POSTTREATMENT SURVEILLANCE AND RE-RESECTION</span><span class="headingEndMark"> — </span>Fewer than 20 percent of patients will recur after surgical therapy, but it is not established which patients are at highest risk [<a href="#rid98">98-102</a>]. Postoperative surveillance typically includes periodic cross-sectional imaging and functional hormonal levels as appropriate, followed by somatostatin receptor-based imaging (eg, 68-Gallium DOTATATE scanning) if a new lesion is identified. However, there is no consensus as to the optimal follow-up strategy, including the frequency of surveillance. Guidelines from the National Comprehensive Cancer Network (NCCN) suggest that the initial assessment occur within 4 to 12 months after resection, followed by repeat assessment every 6 to 12 months to a maximum of ten years [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring"</a>.) </p><p>A nomogram, based on pathological features of the resected specimen, is available to predict likelihood of recurrence [<a href="#rid103">103</a>]. This likelihood can help determine the intensity and frequency of surveillance.</p><p>Reresection should be considered in patients who have evidence of tumor recurrence on postoperative surveillance. </p><p class="headingAnchor" id="H430475439"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111962.html" rel="external">"Society guideline links: Well-differentiated gastroenteropancreatic neuroendocrine tumors"</a>.)</p><p class="headingAnchor" id="H7791166"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – The term "pancreatic neuroendocrine neoplasm (PNEN)" encompasses a diverse set of tumors arising in the pancreas that share a common progenitor cell. PNENs are rare overall and exhibit a wide spectrum of clinical behavior that has made classification and staging difficult. The well-differentiated forms are referred to as "pancreatic neuroendocrine tumors (PNETs)," while high-grade poorly differentiated PNENs are referred to as "pancreatic neuroendocrine carcinomas (PNECs)." (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">While most PNETs are sporadic, PNETs can also be associated with genetic syndromes. The recommendations below refer to sporadic PNETs. The management of PNETs associated with genetic syndromes is discussed separately. (See  <a class="medical medical_review" href="/d/html/2026.html" rel="external">"Multiple endocrine neoplasia type 1: Management"</a> and  <a class="medical medical_review" href="/d/html/5193.html" rel="external">"Clinical features, diagnosis, and management of von Hippel-Lindau disease"</a> and  <a class="medical medical_review" href="/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis"</a> and  <a class="medical medical_review" href="/d/html/90123.html" rel="external">"Neurofibromatosis type 1 (NF1): Management and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor classification</strong> – Terminology is evolving. The current World Health Organization (WHO) classification recognizes three grades of well-differentiated PNETs: low (PanNET G1), intermediate (PanNET G2), or high-grade (PanNET G3); poorly differentiated, high-grade neuroendocrine neoplasms are all referred to as PanNEC G3 tumors  (<a class="graphic graphic_table graphicRef115945" href="/d/graphic/115945.html" rel="external">table 3</a>). We prefer the terms "PNET G1," "PNET G2," and "PNET G3" to designate well-differentiated PNETs of varying grades and "PNEC" to designate a high-grade, poorly differentiated neuroendocrine neoplasm. (See <a class="local">'Staging and tumor classification'</a> above.)</p><p></p><p class="bulletIndent1">For patients with PNEC, surgery alone is rarely curative, even for patients with apparently localized disease. Nevertheless, resection may benefit selected patients when used in conjunction with chemotherapy and/or radiation therapy in a multimodality approach. Management of gastroenteropancreatic NECs is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms", section on 'Localized disease'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of surgery</strong> – Surgery is the only curative modality for sporadic PNETs, and resection of the primary tumor in localized, regional, and even metastatic disease can improve patient survival. The goal of surgical resection of primary, sporadic PNETs is to completely remove the tumor for cure or, in appropriate cases, to debulk the tumor  (<a class="graphic graphic_algorithm graphicRef100577" href="/d/graphic/100577.html" rel="external">algorithm 1</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical indications</strong> – There is some (though decreasing) disagreement among expert groups as to how to manage small (&lt;2 cm) nonfunctioning, well-differentiated PNETs. While the 2016 European Neuroendocrine Tumor Society (ENETS) guidelines and consensus-based guidelines form the National Comprehensive Cancer Network (NCCN) both endorse observation for nonfunctional, well-differentiated, incidentally discovered PNETS &lt;2 cm [<a href="#rid32">32,33</a>], current guidelines from the North American Neuroendocrine Tumor Society have recommended observing PNETS &lt;1 cm and individualizing management of 1 to 2 cm lesions based on age, comorbidities, growth, grade, extent of surgery needed, and patient preference [<a href="#rid34">34</a>]. Until more conclusive data become available, the decision to pursue nonoperative management for small nonfunctional PNETs should be made individually after weighing risks against benefits, with the recognition that the morbidity of any pancreatic resection is considerable. (See <a class="local">'Candidates for resection'</a> above.)</p><p></p><p class="bulletIndent1">Important factors to consider when selecting the surgical approach to sporadic PNETs include functional status, benign or malignant nature, involvement with contiguous structures, presence of metastatic disease, and proliferative index. (See <a class="local">'Staging and tumor classification'</a> above and <a class="local">'Preoperative evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical symptoms and biochemical evidence of hormone excess determine the tumor's functional status, classifying sporadic PNET as nonfunctional or functional (ie, insulinoma, gastrinoma, VIPoma, glucagonoma, or somatostatinoma). Up to one-half of sporadic PNETs have no defined clinical syndrome and no elevated hormone levels. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preoperative imaging by cross-sectional and functional imaging with or without endoscopic ultrasound can help localize the tumor and also determine the tumor's benign or malignant nature by determining the degree of local invasion, lymph node involvement, and metastases to the liver or elsewhere. The only reliable indicators of malignant potential are the presence of invasion, metastases, or tumor recurrence. The majority of glucagonomas, VIPomas, somatostatinomas, and gastrinomas are malignant. Most large, nonfunctional, well-differentiated PNETs are also malignant. (See <a class="local">'Localization and malignant potential'</a> above and <a class="local">'Staging and tumor classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical approaches</strong> – Surgery is indicated in patients with PNETs to alleviate systemic symptoms due to hormone overproduction or compression due to local mass effect and to prevent malignant transformation or dissemination. With malignant tumors, the primary consideration in determining surgical treatment is whether the patient has distant metastatic disease, whether the extrapancreatic disease is potentially resectable, whether metastatic disease is high volume or low volume, and the histology and growth rate. (See <a class="local">'Candidates for resection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with malignant, sporadic PNET and no evidence of distant metastatic spread of disease, exploratory laparotomy and resection with curative intent can be offered. The goal of curative resection is removal of the primary tumor and associated lymph nodes while preserving the maximal amount of pancreatic mass. Surgery for high-grade, poorly differentiated PNETs is rarely beneficial and should only be done in conjunction with chemotherapy and radiation therapy in a multimodality approach.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with malignant, sporadic PNET and potentially resectable metastatic disease, an aggressive resection of the primary and metastatic sites can offer the potential for long-term survival. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with unresectable, metastatic disease, best medical therapy including long-acting somatostatin analogues is the usual first-line approach. In some cases, surgery may be pursued even if complete resection cannot be accomplished. The decision to pursue surgery is a complex one and needs to take into account tumor histology, the volume of metastatic disease, and the growth rate:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with low-volume metastatic well-differentiated low-grade tumors (ie, PanNEN G1), resection of metastatic sites in conjunction with adjuvant therapies such as ablation, embolization, or long-acting somatostatin analogues can prolong and improve the quality of life. Even large tumors can be debulked with the expectation that adjunctive treatment will be used to control unresectable residual disease. (See  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with well-differentiated tumors with high-volume metastatic disease and a rapid growth rate, initial systemic therapy is an appropriate option. However, palliative debulking may still be indicated for relief of systemic or local symptoms related to hormone production. (See  <a class="medical medical_review" href="/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Whether there is a benefit to resection of a primary, nonfunctional PNET in patients with unresectable metastatic disease is debated. In some (but not all) series, this approach is associated with a modest survival benefit, but it is likely that this is the result of selection bias (ie, patients selected for this approach likely had a significantly lower tumor burden). In our view, this decision must be individualized. (See <a class="local">'Candidates for resection'</a> above and <a class="local">'Nonfunctional'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical techniques</strong> – Traditional pancreatic resection (eg, pancreaticoduodenectomy, pancreatic tail resection) and pancreas-sparing resections (enucleation, central pancreatectomy) are used to treat PNETs, depending on the location of the tumor. Parenchyma-sparing operations are generally safe and effective for the management of small PNETs; however, even small PNETs may have lymph node disease and require traditional resection. Enucleation may be attempted for insulinoma and gastrinoma &lt;2 cm that are not abutting the pancreatic duct, as these are likely to be benign. For some patients with significant comorbidities who may not withstand traditional resection, enucleation may also be appropriate. (See <a class="local">'Pancreatic resection'</a> above.)</p><p></p><p class="bulletIndent1">If the PNET is not successfully localized on preoperative imaging, intraoperative localization includes visual and manual inspection of the pancreas and intraoperative ultrasound (IOUS), which can also be used during the course of the procedure to ensure a safe resection. Extrapancreatic sites should also be explored. (See <a class="local">'Intraoperative localization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postsurgical surveillance</strong> – Postoperative surveillance typically includes periodic cross-sectional imaging and functional hormone levels, as appropriate, followed by somatostatin receptor-based imaging if a new lesion is identified. Re-resection should be considered in patients with evidence of tumor recurrence. (See <a class="local">'Posttreatment surveillance and re-resection'</a> above.)</p><p></p><p class="headingAnchor" id="H3865228067"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges James Lee, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008; 19:1727.</a></li><li><a class="nounderline abstract_t">Halfdanarson TR, Rubin J, Farnell MB, et al. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer 2008; 15:409.</a></li><li><a class="nounderline abstract_t">Bilimoria KY, Tomlinson JS, Merkow RP, et al. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg 2007; 11:1460.</a></li><li><a class="nounderline abstract_t">Bilimoria KY, Talamonti MS, Tomlinson JS, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg 2008; 247:490.</a></li><li><a class="nounderline abstract_t">Nissen NN, Kim AS, Yu R, et al. Pancreatic neuroendocrine tumors: presentation, management, and outcomes. Am Surg 2009; 75:1025.</a></li><li><a class="nounderline abstract_t">Fendrich V, Bartsch DK. Surgical treatment of gastrointestinal neuroendocrine tumors. Langenbecks Arch Surg 2011; 396:299.</a></li><li><a class="nounderline abstract_t">Hill JS, McPhee JT, McDade TP, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 2009; 115:741.</a></li><li><a class="nounderline abstract_t">Norton JA. Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg 2006; 10:327.</a></li><li class="breakAll">Edil BH, Ellison T, Cameron JL, et al. Even small pancreatic endocrine neoplasms have lymph node metastasis. Presented at The Pancreas Club meeting, May 2011, Chicago, IL.</li><li><a class="nounderline abstract_t">Scarpa A, Mantovani W, Capelli P, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010; 23:824.</a></li><li class="breakAll">Bergsland EK, Woltering EA, Rindo G. Neuroendocrine tumors of the pancreas. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.407. Corrected at 4th printing, 2018.</li><li><a class="nounderline abstract_t">Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341:635.</a></li><li><a class="nounderline abstract_t">Harris AG, O'Dorisio TM, Woltering EA, et al. Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. Dig Dis Sci 1995; 40:1464.</a></li><li><a class="nounderline abstract_t">Abood GJ, Go A, Malhotra D, Shoup M. The surgical and systemic management of neuroendocrine tumors of the pancreas. Surg Clin North Am 2009; 89:249.</a></li><li><a class="nounderline abstract_t">Eriksson B, Oberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993; 32:203.</a></li><li><a class="nounderline abstract_t">Fernández-Cruz L, Blanco L, Cosa R, Rendón H. Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg 2008; 32:904.</a></li><li><a class="nounderline abstract_t">Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395.</a></li><li><a class="nounderline abstract_t">Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451:757.</a></li><li class="breakAll">American Joint Committee on Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.</li><li><a class="nounderline abstract_t">Boninsegna L, Panzuto F, Partelli S, et al. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer 2012; 48:1608.</a></li><li><a class="nounderline abstract_t">Klöppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2011; 18 Suppl 1:S1.</a></li><li><a class="nounderline abstract_t">Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 2011; 29:2372.</a></li><li class="breakAll">Kloppel G, Couvelard A, Hruban RH, Klimstra DS. WHO classification of neoplasms of the neuroendocrine pancreas. In: WHO Classification of Tumours of Endocrine Organs, 4th ed, Lloyd RV, Osamura RY, Kloppel G, Rosai J. (Eds), International Agency for Research on Cancer, Lyon 2017. p.210.</li><li><a class="nounderline abstract_t">Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 2007; 25:5609.</a></li><li><a class="nounderline abstract_t">Bettini R, Partelli S, Boninsegna L, et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 2011; 150:75.</a></li><li><a class="nounderline abstract_t">Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010; 39:735.</a></li><li><a class="nounderline abstract_t">Akerström G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21:87.</a></li><li><a class="nounderline abstract_t">Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res 2004; 120:139.</a></li><li><a class="nounderline abstract_t">Phan GQ, Yeo CJ, Hruban RH, et al. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg 1998; 2:473.</a></li><li><a class="nounderline abstract_t">Pitt SC, Pitt HA, Baker MS, et al. Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? J Gastrointest Surg 2009; 13:1692.</a></li><li><a class="nounderline abstract_t">Partelli S, Cirocchi R, Crippa S, et al. Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. Br J Surg 2017; 104:34.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2016; 103:153.</a></li><li><a class="nounderline abstract_t">Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas 2020; 49:1.</a></li><li><a class="nounderline abstract_t">Nguyen SQ, Angel LP, Divino CM, et al. Surgery in malignant pancreatic neuroendocrine tumors. J Surg Oncol 2007; 96:397.</a></li><li><a class="nounderline abstract_t">Nomura N, Fujii T, Kanazumi N, et al. Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg 2009; 16:639.</a></li><li><a class="nounderline abstract_t">Hung JS, Chang MC, Lee PH, Tien YW. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? World J Surg 2007; 31:2392.</a></li><li><a class="nounderline abstract_t">Bruzoni M, Parikh P, Celis R, et al. Management of the primary tumor in patients with metastatic pancreatic neuroendocrine tumor: a contemporary single-institution review. Am J Surg 2009; 197:376.</a></li><li><a class="nounderline abstract_t">Norton JA, Kivlen M, Li M, et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 2003; 138:859.</a></li><li><a class="nounderline abstract_t">Schurr PG, Strate T, Rese K, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg 2007; 245:273.</a></li><li><a class="nounderline abstract_t">Abu Hilal M, McPhail MJ, Zeidan BA, et al. Aggressive multi-visceral pancreatic resections for locally advanced neuroendocrine tumours. Is it worth it? JOP 2009; 10:276.</a></li><li><a class="nounderline abstract_t">Franko J, Feng W, Yip L, et al. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Surg 2010; 14:541.</a></li><li><a class="nounderline abstract_t">Chu QD, Hill HC, Douglass HO Jr, et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002; 9:855.</a></li><li><a class="nounderline abstract_t">Kazanjian KK, Reber HA, Hines OJ. Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 2006; 141:765.</a></li><li><a class="nounderline abstract_t">Birnbaum DJ, Turrini O, Vigano L, et al. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study. Ann Surg Oncol 2015; 22:1000.</a></li><li><a class="nounderline abstract_t">Birnbaum DJ, Gaujoux S, Cherif R, et al. Sporadic nonfunctioning pancreatic neuroendocrine tumors: prognostic significance of incidental diagnosis. Surgery 2014; 155:13.</a></li><li><a class="nounderline abstract_t">Bahra M, Jacob D, Pascher A, et al. Surgical strategies and predictors of outcome for malignant neuroendocrine tumors of the pancreas. J Gastroenterol Hepatol 2007; 22:930.</a></li><li><a class="nounderline abstract_t">Fischer L, Kleeff J, Esposito I, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 2008; 95:627.</a></li><li><a class="nounderline abstract_t">Bonney GK, Gomez D, Rahman SH, et al. Results following surgical resection for malignant pancreatic neuroendocrine tumours. A single institutional experience. JOP 2008; 9:19.</a></li><li><a class="nounderline abstract_t">Norton JA, Harris EJ, Chen Y, et al. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg 2011; 146:724.</a></li><li><a class="nounderline abstract_t">Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197:29.</a></li><li><a class="nounderline abstract_t">Dixon E, Pasieka JL. Functioning and nonfunctioning neuroendocrine tumors of the pancreas. Curr Opin Oncol 2007; 19:30.</a></li><li><a class="nounderline abstract_t">Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190:432.</a></li><li><a class="nounderline abstract_t">Oberg K, Ferone D, Kaltsas G, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. Neuroendocrinology 2009; 90:209.</a></li><li><a class="nounderline abstract_t">Plöckinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80:394.</a></li><li><a class="nounderline abstract_t">Gomez-Rivera F, Stewart AE, Arnoletti JP, et al. Surgical treatment of pancreatic endocrine neoplasms. Am J Surg 2007; 193:460.</a></li><li><a class="nounderline abstract_t">Allendorf JD, Schrope BA, Lauerman MH, et al. Postoperative glycemic control after central pancreatectomy for mid-gland lesions. World J Surg 2007; 31:164.</a></li><li><a class="nounderline abstract_t">DiNorcia J, Ahmed L, Lee MK, et al. Better preservation of endocrine function after central versus distal pancreatectomy for mid-gland lesions. Surgery 2010; 148:1247.</a></li><li><a class="nounderline abstract_t">Warshaw AL. Conservation of the spleen with distal pancreatectomy. Arch Surg 1998; 123:550.</a></li><li><a class="nounderline abstract_t">Warshaw AL. Distal pancreatectomy with preservation of the spleen. J Hepatobiliary Pancreat Sci 2010; 17:808.</a></li><li><a class="nounderline abstract_t">Falconi M, Zerbi A, Crippa S, et al. Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. Ann Surg Oncol 2010; 17:1621.</a></li><li><a class="nounderline abstract_t">Crippa S, Bassi C, Warshaw AL, et al. Middle pancreatectomy: indications, short- and long-term operative outcomes. Ann Surg 2007; 246:69.</a></li><li><a class="nounderline abstract_t">Müller MW, Friess H, Kleeff J, et al. Middle segmental pancreatic resection: An option to treat benign pancreatic body lesions. Ann Surg 2006; 244:909.</a></li><li><a class="nounderline abstract_t">Adham M, Giunippero A, Hervieu V, et al. Central pancreatectomy: single-center experience of 50 cases. Arch Surg 2008; 143:175.</a></li><li><a class="nounderline abstract_t">Hirono S, Tani M, Kawai M, et al. A central pancreatectomy for benign or low-grade malignant neoplasms. J Gastrointest Surg 2009; 13:1659.</a></li><li><a class="nounderline abstract_t">Sudo T, Murakami Y, Uemura K, et al. Middle pancreatectomy with pancreaticogastrostomy: a technique, operative outcomes, and long-term pancreatic function. J Surg Oncol 2010; 101:61.</a></li><li><a class="nounderline abstract_t">Shikano T, Nakao A, Kodera Y, et al. Middle pancreatectomy: safety and long-term results. Surgery 2010; 147:21.</a></li><li><a class="nounderline abstract_t">Zhou J, Dong M, Kong F, et al. Central pancreatectomy for benign tumors of the neck and body of the pancreas: report of eight cases. J Surg Oncol 2009; 100:273.</a></li><li><a class="nounderline abstract_t">Lavu H, Knuth JL, Baker MS, et al. Middle segment pancreatectomy can be safely incorporated into a pancreatic surgeon's clinical practice. HPB (Oxford) 2008; 10:491.</a></li><li><a class="nounderline abstract_t">Roggin KK, Rudloff U, Blumgart LH, Brennan MF. Central pancreatectomy revisited. J Gastrointest Surg 2006; 10:804.</a></li><li><a class="nounderline abstract_t">Sauvanet A, Partensky C, Sastre B, et al. Medial pancreatectomy: a multi-institutional retrospective study of 53 patients by the French Pancreas Club. Surgery 2002; 132:836.</a></li><li><a class="nounderline abstract_t">Christein JD, Smoot RL, Farnell MB. Central pancreatectomy: a technique for the resection of pancreatic neck lesions. Arch Surg 2006; 141:293.</a></li><li><a class="nounderline abstract_t">King J, Kazanjian K, Matsumoto J, et al. Distal pancreatectomy: incidence of postoperative diabetes. J Gastrointest Surg 2008; 12:1548.</a></li><li><a class="nounderline abstract_t">Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135:1469.</a></li><li><a class="nounderline abstract_t">DiNorcia J, Schrope BA, Lee MK, et al. Laparoscopic distal pancreatectomy offers shorter hospital stays with fewer complications. J Gastrointest Surg 2010; 14:1804.</a></li><li><a class="nounderline abstract_t">DiNorcia J, Lee MK, Reavey PL, et al. One hundred thirty resections for pancreatic neuroendocrine tumor: evaluating the impact of minimally invasive and parenchyma-sparing techniques. J Gastrointest Surg 2010; 14:1536.</a></li><li><a class="nounderline abstract_t">Tian F, Hong XF, Wu WM, et al. Propensity score-matched analysis of robotic versus open surgical enucleation for small pancreatic neuroendocrine tumours. Br J Surg 2016; 103:1358.</a></li><li><a class="nounderline abstract_t">Bettini R, Mantovani W, Boninsegna L, et al. Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis 2009; 41:49.</a></li><li><a class="nounderline abstract_t">Keutgen XM, Nilubol N, Glanville J, et al. Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors. Surgery 2016; 159:311.</a></li><li><a class="nounderline abstract_t">Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001; 130:1078.</a></li><li><a class="nounderline abstract_t">Howard TJ, Stabile BE, Zinner MJ, et al. Anatomic distribution of pancreatic endocrine tumors. Am J Surg 1990; 159:258.</a></li><li><a class="nounderline abstract_t">Thompson GB, Service FJ, van Heerden JA, et al. Reoperative insulinomas, 1927 to 1992: an institutional experience. Surgery 1993; 114:1196.</a></li><li><a class="nounderline abstract_t">Jackson JE. Angiography and arterial stimulation venous sampling in the localization of pancreatic neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2005; 19:229.</a></li><li><a class="nounderline abstract_t">Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 1992; 112:1024.</a></li><li><a class="nounderline abstract_t">Modlin IM, Lewis JJ, Ahlman H, et al. Management of unresectable malignant endocrine tumors of the pancreas. Surg Gynecol Obstet 1993; 176:507.</a></li><li><a class="nounderline abstract_t">McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108:1091.</a></li><li><a class="nounderline abstract_t">Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol 2005; 19:783.</a></li><li><a class="nounderline abstract_t">de Herder WW, Niederle B, Scoazec JY, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006; 84:183.</a></li><li><a class="nounderline abstract_t">Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008; 113:1807.</a></li><li><a class="nounderline abstract_t">Fishbeyn VA, Norton JA, Benya RV, et al. Assessment and prediction of long-term cure in patients with the Zollinger-Ellison syndrome: the best approach. Ann Intern Med 1993; 119:199.</a></li><li><a class="nounderline abstract_t">Norton JA, Alexander HR, Fraker DL, et al. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg 2004; 239:617.</a></li><li><a class="nounderline abstract_t">Ehehalt F, Saeger HD, Schmidt CM, Grützmann R. Neuroendocrine tumors of the pancreas. Oncologist 2009; 14:456.</a></li><li><a class="nounderline abstract_t">Jensen RT, Niederle B, Mitry E, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006; 84:173.</a></li><li><a class="nounderline abstract_t">Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007; 14:3492.</a></li><li><a class="nounderline abstract_t">Smith SL, Branton SA, Avino AJ, et al. Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery 1998; 124:1050.</a></li><li><a class="nounderline abstract_t">Chu QD, Al-kasspooles MF, Smith JL, et al. Is glucagonoma of the pancreas a curable disease? Int J Pancreatol 2001; 29:155.</a></li><li><a class="nounderline abstract_t">House MG, Yeo CJ, Schulick RD. Periampullary pancreatic somatostatinoma. Ann Surg Oncol 2002; 9:869.</a></li><li><a class="nounderline abstract_t">Kim H, Song KB, Hwang DW, et al. Time-trend and recurrence analysis of pancreatic neuroendocrine tumors. Endocr Connect 2019; 8:1052.</a></li><li><a class="nounderline abstract_t">Kwon W, Jang JY, Song KB, et al. Risk Factors for Recurrence in Pancreatic Neuroendocrine Tumor and Size as a Surrogate in Determining the Treatment Strategy: A Korean Nationwide Study. Neuroendocrinology 2021; 111:794.</a></li><li><a class="nounderline abstract_t">Yamamoto Y, Okamura Y, Uemura S, et al. Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor. Ann Surg Oncol 2017; 24:2363.</a></li><li><a class="nounderline abstract_t">Wang WQ, Zhang WH, Gao HL, et al. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors. J Gastroenterol 2021; 56:395.</a></li><li><a class="nounderline abstract_t">Li Y, Fan G, Yu F, et al. Meta-Analysis of Prognostic Factors for Recurrence of Resected Well-Differentiated Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2021; 111:1231.</a></li><li><a class="nounderline abstract_t">Pulvirenti A, Javed AA, Landoni L, et al. Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors. Ann Surg 2021; 274:1051.</a></li></ol></div><div id="topicVersionRevision">Topic 15045 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18515795" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18508996" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17846854" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18376195" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19886158" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pancreatic neuroendocrine tumors: presentation, management, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21279821" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Surgical treatment of gastrointestinal neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19130464" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16504877" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Surgery for primary pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16504877" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Surgery for primary pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20305616" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20305616" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10460814" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Surgery to cure the Zollinger-Ellison syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7628270" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19186239" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The surgical and systemic management of neuroendocrine tumors of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8391832" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : An update of the medical treatment of malignant endocrine pancreatic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18264824" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16967267" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17674042" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17674042" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22129889" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22005112" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21555696" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21555696" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18065733" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21683859" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664472" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17382267" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Surgery on neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15172200" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pancreatic endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18335273" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19548038" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27706803" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27706803" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26742109" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31856076" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17469119" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Surgery in malignant pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19365596" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nonfunctioning neuroendocrine pancreatic tumors: our experience and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17960455" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19245918" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Management of the primary tumor in patients with metastatic pancreatic neuroendocrine tumor: a contemporary single-institution review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12912744" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17245182" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19454819" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Aggressive multi-visceral pancreatic resections for locally advanced neuroendocrine tumours. Is it worth it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19997980" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12417506" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16924083" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Resection of pancreatic neuroendocrine tumors: results of 70 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25190116" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24238123" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Sporadic nonfunctioning pancreatic neuroendocrine tumors: prognostic significance of incidental diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17489964" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Surgical strategies and predictors of outcome for malignant neuroendocrine tumors of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18306152" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18182738" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Results following surgical resection for malignant pancreatic neuroendocrine tumours. A single institutional experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21690450" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12831921" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133109" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Functioning and nonfunctioning neuroendocrine tumors of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10757381" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hepatic neuroendocrine metastases: does intervention alter outcomes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19077379" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15838182" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17368289" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Surgical treatment of pancreatic endocrine neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17171499" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Postoperative glycemic control after central pancreatectomy for mid-gland lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21134558" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Better preservation of endocrine function after central versus distal pancreatectomy for mid-gland lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Conservation of the spleen with distal pancreatectomy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19882099" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Distal pancreatectomy with preservation of the spleen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20162460" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17592293" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Middle pancreatectomy: indications, short- and long-term operative outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17122616" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Middle segmental pancreatic resection: An option to treat benign pancreatic body lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18283143" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Central pancreatectomy: single-center experience of 50 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19488821" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A central pancreatectomy for benign or low-grade malignant neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19894223" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Middle pancreatectomy with pancreaticogastrostomy: a technique, operative outcomes, and long-term pancreatic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19682717" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Middle pancreatectomy: safety and long-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19267362" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Central pancreatectomy for benign tumors of the neck and body of the pancreas: report of eight cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19088938" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Middle segment pancreatectomy can be safely incorporated into a pancreatic surgeon's clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16769536" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Central pancreatectomy revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12464868" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Medial pancreatectomy: a multi-institutional retrospective study of 53 patients by the French Pancreas Club.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549696" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Central pancreatectomy: a technique for the resection of pancreatic neck lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18543045" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Distal pancreatectomy: incidence of postoperative diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703061" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20589446" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Laparoscopic distal pancreatectomy offers shorter hospital stays with fewer complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20824378" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : One hundred thirty resections for pancreatic neuroendocrine tumor: evaluating the impact of minimally invasive and parenchyma-sparing techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27480993" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Propensity score-matched analysis of robotic versus open surgical enucleation for small pancreatic neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18463008" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26453135" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11742342" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2154144" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Anatomic distribution of pancreatic endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8256226" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Reoperative insulinomas, 1927 to 1992: an institutional experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15763697" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Angiography and arterial stimulation venous sampling in the localization of pancreatic neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1455305" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Prospective study of aggressive resection of metastatic pancreatic endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8386860" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Management of unresectable malignant endocrine tumors of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1701060" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cytoreductive hepatic surgery for neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16253900" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Insulinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17312378" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Well-differentiated pancreatic tumor/carcinoma: insulinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18798544" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8323088" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Assessment and prediction of long-term cure in patients with the Zollinger-Ellison syndrome: the best approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15082965" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19411317" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Neuroendocrine tumors of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17312377" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Gastrinoma (duodenal and pancreatic).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17896148" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Population-based study of islet cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854582" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12067219" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Is glucagonoma of the pancreas a curable disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12417508" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Periampullary pancreatic somatostatinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31252400" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Time-trend and recurrence analysis of pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33002889" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Risk Factors for Recurrence in Pancreatic Neuroendocrine Tumor and Size as a Surrogate in Determining the Treatment Strategy: A Korean Nationwide Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28271173" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33742253" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33370727" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Meta-Analysis of Prognostic Factors for Recurrence of Resected Well-Differentiated Pancreatic Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31567347" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
